IP Library Granted Patent US 11,707,431
Granted Patent B2
US 11,707,431 · App. 16/604,135 · Granted Jul 25, 2023

Dental strips for the delivery of specifically targeted antimicrobial peptides

Inventors: Evan Schauer (Los Angeles, CA); Miroslav Baudys (Marina Del Rey, CA); Brian C. Varnum (Santa Monica, CA); Duane Morris (Santa Monica, CA); Christopher W. Kaplan (Los Angeles, CA); Randal H. Eckert (Ellensburg, WA)
Assignee: C3 Jian, LLC
A61K9/006A61K38/10A61K38/164A61K47/32A61K47/34A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,707,431
App. No.
16/604,135
Granted
Jul 25, 2023
Kind
B2
Abstract

In certain embodiments a dental strip for the prevention or reduction of dental caries is provided. In certain embodiments the dental strip is constructed to deliver effective amounts of specifically targeted antimicrobial peptides (or simple antimicrobial peptides) and comprises an orally compatible backing layer, a delivery layer disposed on one surface of the backing layer where the delivery layer comprises an orally compatible polymer, or combination of polymers, and a specifically targeted antimicrobial peptide (and/or simple antimicrobial peptide) capable of binding and killing Streptococcus mutans . In certain embodiments the dental strip additionally comprises a release liner.

Claims (101)

1. A dental strip for the delivery of effective amounts of specifically targeted antimicrobial peptides (STAMPs), said dental strip comprising:

an orally compatible backing layer; and

a delivery layer disposed on one surface of said backing layer wherein said delivery layer comprises:

about 90 mg to 100 mg polyvinylpyrrolidone (K90);

about 5 mg up to about 80 mg of a specifically targeted antimicrobial peptide (STAMP) capable of binding and killing Streptococcus mutans;

about 3 mg up to about 4 mg sucralose as a first flavoring agent;

about 20 mg up to about 30 mg of a second flavoring agent other than sucralose; and

a coloring agent;

wherein said delivery layer maintains the stability and activity of the STAMP and releases an effective amount of said STAMP when said dental strip is disposed against teeth in an oral cavity; and

wherein said STAMP comprises a targeting peptide comprising an amino acid sequence selected from the group consisting of SGSLSTFFRLFNRSFTQALGK (SEQ ID NO:5), EMRLSKFFRDFILQRKK (SEQ ID NO:6), EMRISRIILDFLFLRKK (SEQ ID NO:7), NIFEYFLE (SEQ ID NO:8), TFFRLFNR (SEQ ID NO:9), TFFRLFNRS (SEQ ID NO:10), TFFRLFNRS (SEQ ID NO:11), TFFRLFNRSF (SEQ ID NO:12), TFFRLFNRSFT (SEQ ID NO:13), TFFRLFNRSFTQ (SEQ ID NO:14), TFFRLFNRSFTQA (SEQ ID NO:15), TFFRLFNRSFTQAL (SEQ ID NO:16), TFFRLFNRSFTQALG (SEQ ID NO:17), TFFRLFNRSFTQALGK (SEQ ID NO:18), STFFRLFNR (SEQ ID NO:19), STFFRLFNRS (SEQ ID NO:20), STFFRLFNRS (SEQ ID NO:21), STFFRLFNRSF (SEQ ID NO:22), STFFRLFNRSFT (SEQ ID NO:23), STFFRLFNRSFTQ (SEQ ID NO:24), STFFRLFNRSFTQA (SEQ ID NO:25), STFFRLFNRSFTQAL (SEQ ID NO:26), STFFRLFNRSFTQALG (SEQ ID NO:27), STFFRLFNRSFTQALGK (SEQ ID NO:28), LSTFFRLFNR (SEQ ID NO:29), LSTFFRLFNRS (SEQ ID NO:30), LSTFFRLFNRS (SEQ ID NO:31), LSTFFRLFNRSF (SEQ ID NO:32), LSTFFRLFNRSFT (SEQ ID NO:33), LSTFFRLFNRSFTQ (SEQ ID NO:34), LSTFFRLFNRSFTQA (SEQ ID NO:35), LSTFFRLFNRSFTQAL (SEQ ID NO:36), LSTFFRLFNRSFTQALG (SEQ ID NO:37), LSTFFRLFNRSFTQALGK (SEQ ID NO:38), SLSTFFRLFNR (SEQ ID NO:39), SLSTFFRLFNRS (SEQ ID NO:40), SLSTFFRLFNRS (SEQ ID NO:41), SLSTFFRLFNRSF (SEQ ID NO:42), SLSTFFRLFNRSFT (SEQ ID NO:43), SLSTFFRLFNRSFTQ (SEQ ID NO:44), SLSTFFRLFNRSFTQA (SEQ ID NO:45), SLSTFFRLFNRSFTQAL (SEQ ID NO:46), SLSTFFRLFNRSFTQALG (SEQ ID NO:47), SLSTFFRLFNRSFTQALGK (SEQ ID NO:48), GSLSTFFRLFNR (SEQ ID NO:49), GSLSTFFRLFNRS (SEQ ID NO:50), GSLSTFFRLFNRS (SEQ ID NO:51), GSLSTFFRLFNRSF (SEQ ID NO:52), GSLSTFFRLFNRSFT (SEQ ID NO:53), GSLSTFFRLFNRSFTQ (SEQ ID NO:54), GSLSTFFRLFNRSFTQA (SEQ ID NO:55), GSLSTFFRLFNRSFTQAL (SEQ ID NO:56), GSLSTFFRLFNRSFTQALG (SEQ ID NO:57), GSLSTFFRLFNRSFTQALGK (SEQ ID NO:58), SGSLSTFFRLFNR (SEQ ID NO:59), SGSLSTFFRLFNRS (SEQ ID NO:60), SGSLSTFFRLFNRS (SEQ ID NO:61), SGSLSTFFRLFNRSF (SEQ ID NO:62), SGSLSTFFRLFNRSFT (SEQ ID NO:63), SGSLSTFFRLFNRSFTQ (SEQ ID NO:64), SGSLSTFFRLFNRSFTQA (SEQ ID NO:65), SGSLSTFFRLFNRSFTQAL (SEQ ID NO:66), and SGSLSTFFRLFNRSFTQALG (SEQ ID NO:67), AFFRAFNRAFAQALAK (SEQ ID NO:70), TFFRAFARAFAQAAAK (SEQ ID NO:71), AFFRAFARAFAQALAK (SEQ ID NO:72), AFFRLFARAFAQAAAK (SEQ ID NO:73), TLFRLLNRSLTQALGK (SEQ ID NO:74), TFFRLFNRSFTQALFK (SEQ ID NO:75), TFFRLFNRSLTQALGK (SEQ ID NO:76), TFFRLFNRSFTQALNK (SEQ ID NO:77), AFFRAFARAFAQAAAK (SEQ ID NO:78), AFFRAFNRAFAQAAAK (SEQ ID NO:79), TFFRLFNRSFTQALSK (SEQ ID NO:80), AFFRAFARSFAQAAAK (SEQ ID NO:81), AFFRAFARAFAQAAGK (SEQ ID NO:82), AFFRAFARAFTQAAAK (SEQ ID NO:83), TFFRLFNRSFTQALGQ (SEQ ID NO:84), TFFRLLNRSFTQALGK (SEQ ID NO:85), TWFRLFNRSFTQALGK (SEQ ID NO:86), AFFRAFARAFAQAFAK (SEQ ID NO:87), TQFRLFNRSFTQALGK (SEQ ID NO:88), TFFRLFNRSFTQALDK (SEQ ID NO:89), TFFRLFNRSFTQALAK (SEQ ID NO:90), TFFRLFNRSFTQALGE (SEQ ID NO:91), TFFRLFSRSFTQALGK (SEQ ID NO:92), TFFRLFNRSFTQALGA (SEQ ID NO:93), TFFRLFDRSFTQALGK (SEQ ID NO:94), TFFRLFNRSFTQALGF (SEQ ID NO:95), TFFRAFARSFTQAAAK (SEQ ID NO:96), TFFRLFARSFTQAAGK (SEQ ID NO:97), TFFRLFNRSFTQ L K (SEQ ID NO:98), TFFRLFNRSFTQALGS (SEQ ID NO:99), TLFRLFNRSFTQALGK (SEQ ID NO:100), TFFRLNFRSFTQALGK (SEQ ID NO:101), TFFRLFNRSQTQALGK (SEQ ID NO:102), TFFRLFAAAFTQALGK (SEQ ID NO:103), TFFRLFNRSFTQALGK (SEQ ID NO:104), TFFRLFNRSAAAALGK (SEQ ID NO:105), TFFRLFFRSNTQALGK (SEQ ID NO:106), TFFRLFNRSFTQPLGK (SEQ ID NO:107), TAFRLANRSATQALGK (SEQ ID NO:108), TFFRLFNRSFTQAAAA (SEQ ID NO:109), TFFRLQNRSFTQALGK (SEQ ID NO:110), TFFRLFNRSFTQALPK (SEQ ID NO:111), TYYRLFNRSFTQALGK (SEQ ID NO:112), TFFRLF RSFTQALGK (SEQ ID NO:113), and TQFRLQNRSQTQALGK (SEQ ID NO:114) attached to an antimicrobial peptide comprising an amino acid sequence selected from the group consisting of KNLRIIRKGIHIIKKY (SEQ ID NO:4), GLGRVIGRLIKQIIWRR (SEQ ID NO:123), VYRKRKSILKIYAKLKGWH (SEQ ID NO:124), NYRLVNAIFSKIFKKKFIKF (SEQ ID NO:125), KILKFLFKKVF (SEQ ID NO:126), FIRKFLKKWLL (SEQ ID NO:127), KLFKFLRKHLL (SEQ ID NO:128), KILKFLFKQVF (SEQ ID NO:129), KILKKLFKFVF (SEQ ID NO:130), GILKKLFTKVF (SEQ ID NO:131), LRKFLHKLF (SEQ ID NO:132), LRKNLRWLF (SEQ ID NO:133), FIRKFLQKLHL (SEQ ID NO:134), FTRKFLKFLHL (SEQ ID NO:135), KKFKKFKVLKIL (SEQ ID NO:136), LLKLLKLKKLKF (SEQ ID NO:137), FLKFLKKFFKKLKY (SEQ ID NO:138), GWLKMFKKIIGKFGKF (SEQ ID NO:139), GIFKKFVKILYKVQKL (SEQ ID NO:140), YIQFHLNQQPRPKVKKIKIFL (SEQ ID NO:142), FESKILNASKELDKEKKVNTALSFNSHQDFAKAYQNGKI (SEQ ID NO:145), and WSRVPGHSDTGWKVWHRW (SEQ ID NO:146).

2. The dental strip of claim 1 , wherein:

said delivery layer is distributed on said backing layer as a plurality of dots or regions; or

said delivery layer is distributed on said backing layer as a substantially continuous layer.

3. The dental strip of claim 1 , wherein said delivery layer ranges in thickness from about 20 μm up to about 500 μm.

4. The dental strip of claim 1 , wherein:

said dental strip, when applied to a tooth surface delivers sufficient specifically targeted antimicrobial peptide to kill or to inhibit the growth and/or proliferation of S. mutans on said tooth surface and/or adjacent gums; and/or

said delivery layer is provided on said strip in a substantially dry form or the orally compatible polymer comprising said delivery layer is hydratable and/or dissolvable in the mouth; and/or

said orally compatible polymer dissolves over a period of time ranging from about 1 minute or from about 2 minutes or from about 5 minutes, or from about 10 minutes up to about 1 hour, or up to about 45 minutes, or up to about 30 minutes, or up to about 20 minutes.

5. The dental strip of claim 1 , wherein:

said backing layer comprises one or more materials selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, and polyethylene glycol; or

said backing layer is water impermeable; or

said backing layer comprises a material selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene, polypropylene, polyolefin, polyurethane, polyethylene terephthalate, polylactic acid, polyacrylates, and ethylene vinyl acetate.

6. The dental strip of claim 1 , wherein a release liner film is disposed on said delivery layer.

7. The dental strip of claim 6 , wherein:

said release liner can be peeled from the underlying delivery layer without substantially removing said delivery layer from said backing layer; and/or

said release liner comprises a material selected from the group consisting of polyethylene, polypropylene, various polyurethanes, polyethylene terephthalate, polytetrafluoroethylene, polysiloxanes, and combinations thereof; and/or

said release liner comprises a polyethylene terephthalate and polytetrafluoroethylene film; and/or

said release liner ranges in thickness from about 10 μm to about 200 μm, or about 25 μm to about 100 μm, or about 80 μm.

8. The dental strip of claim 1 , wherein said dental strip comprises about 25 mg to about 30 mg of said second flavoring agent.

9. The dental strip of claim 8 , wherein said backing layer comprises ethylcellulose with a viscosity of 90 to 110 mPa as a 5% solution in 80% toluene, 20% ethanol.

10. The dental strip of claim 1 , wherein the delivery layer comprises a formulation selected from the group consisting of:

Component

Function

Amount per Strip

Specifically targeted

Active Agent

 9.2 mg

antimicrobial peptide

Polyvinylpyrrolidone, K90

Polymer

94.7 mg

Sucralose, NF

Flavoring Agent

 3.2 mg

Cool Mint Flavor

Flavoring agent

26.3 mg

FD&C Blue No. 1

Coloring Agent

 0.1 mg,

Component

Function

Strip

Specifically targeted

Active Agent

18.4 mg

antimicrobial peptide

Polyvinylpyrrolidone, K90

Polymer

94.7 mg

Sucralose, NF

Flavoring Agent

 3.2 mg

Cool Mint Flavor

Flavoring agent

26.3 mg

FD&C Blue No. 1

Coloring Agent

 0.1 mg,

and

Component

Function

Amount per strip

Specifically targeted

Active Agent

36.8 mg

antimicrobial peptide

Polyvinylpyrrolidone, K90

Polymer

95.7 mg

Sucralose, NF

Flavoring Agent

 3.7 mg

Cool Mint Flavor

Flavoring agent

26.1 mg

FD&C Blue No. 1

Coloring Agent

 0.1 mg.

11. The dental strip of claim 1 , wherein:

the amino acid sequence of said targeting peptide consists of the sequence TFFRLFNRSFTQALGK (SEQ ID NO:104); and

the amino acid sequence of said antimicrobial peptide consists of the sequence KNLRIIRKGIHIIKKY (SEQ ID NO:4).

12. The dental strip of claim 1 , wherein:

said dental strip contains a fluoride; and/or

said dental strip comprises a fluoride disposed in said delivery layer; and/or

said dental strip comprises a fluoride selected from the group consisting of sodium fluoride, stannous fluoride, sodium monofluorophosphate, zinc hexafluorosilicate, sodium hexafluorosilicate, ammonium fluoride, calcium fluoro-phosphate (Ca 5 [F(PO 4 ) 3 ]) or fluorapatite, fluorine-doped hydroxyapatite, calcium fluoride (CaF 2 ) or fluorite or fluorspar, diofluorisilane, TiF 4 , and acidulated fluoride; and/or

said dental strip additionally contains a positively charged compound that is antimicrobial and/or that promotes remineralization; and/or

said dental strip contains a compound selected from the group consisting of cetylpyridinium chloride, benzalkonium chloride, chlorhexidine, polyhexamethylene biguanide (PHMB), cationic antimicrobial nanoparticles, bleach, synthetic peptides comprising a single DSS or ESS or repeats of DSS or ESS, dentin-sialophosphoprotein (DSP), dentin phosphoprotein, Arg-calcium carbonate, and xylitol.

13. A method of reducing or preventing the formation of dental caries disease in a mammal, said method comprising applying a dental strip of claim 1 to the teeth of said mammal.

14. A kit comprising:

a container containing a dental strip of claim 1 .

Assignments (7)
SECURITY INTEREST Recorded May 20, 2026
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 074715/0208 →
SECURITY INTEREST Recorded Aug 14, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 072025/0567 →
SECURITY INTEREST Recorded Mar 17, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 070532/0979 →
SECURITY INTEREST Recorded Mar 5, 2024
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 066657/0409 →
SECURITY INTEREST Recorded Jul 14, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 064262/0958 →
SECURITY INTEREST Recorded Feb 17, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 062733/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2022
From: SCHAUER, EVAN; BAUDYS, MIROSLAV; VARNUM, BRIAN C.; MORRIS, DUANE; KAPLAN, CHRISTOPHER W.; ECKERT, RANDAL H.
To: C3 JIAN, LLC
Reel/Frame 060944/0126 →
Continuity (2)
Provisional Application 62485793 · Apr 14, 2017
Related Publication 20200113818A1 · Apr 16, 2020